The Perils Of Ignoring Patients In Drug Development
Lack of early patient involvement in trial design can lead to burdensome studies, inappropriate endpoints, and in some cases clinical failure, delegates heard at a recent regulatory meeting.
You may also be interested in...
IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”
Canada’s health technology appraisal body is seeking feedback on guidance on the use of real-world evidence in decision making.
ANVISA, Brazil’s medicines regulator, is asking for feedback on the regulatory pathway for biosimilars.